Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902133 | 0.80 | CXCR2 (0.59) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18059460 | 0.80 | L3MBTL1 (0.48) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16011599 | 0.80 | L3MBTL1 (0.50) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2995142 | 0.80 | L3MBTL1 (0.48) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19859227 | 0.80 | SCN9A (0.49) | HSD17B10NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL11973215 | 0.80 | L3MBTL1 (0.48) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15359704 | 0.80 | L3MBTL1 (0.48) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19970154 | 0.80 | SMN1; SMN2 (0.50) | HSD17B10NPC1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL2887792 | 0.80 | SCN9A (0.52) | HSD17B10RAB9AMEN1HTTKMT2A | |
| SCHEMBL30553438 | 0.80 | L3MBTL1 (0.48) | L3MBTL1HSD17B10NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4616087-A | ANTIVIRAL ACTIVITY | THE DOW CHEMICAL COMPANY (US) | 1986-10-07 | — | — | US | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-4616087-A | ANTIVIRAL ACTIVITY | THE DOW CHEMICAL COMPANY (US) | 1986-10-07 | — | — | US | disclosed |
| US-4371537-A | Sulfur-substituted phenoxypyridines having antiviral activity | THE DOW CHEMICAL COMPANY (US) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | L3MBTL1 4324/4885HSD17B10 954/4885NPC1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.